N/A N=167 A Comparison of Narrow Band Imaging (NBI) and Standard White Light Laparoscopy to Detect Endometriosis
Endometriosis
Primary: Diagnostic Yield — 81; 25 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=8 Evaluation of Endometriosis With 18F-fluoroestradiol PET / MRI
Endometriosis
Primary: Sensitivity of FES PET/MRI for Evaluating Endometriosis (Percentage of Positive Scans) — 67 percentage of positive scans — p=0.317
Phase 2 N=67 Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis
Endometriosis
Primary: Changes in the Sizes (mm) of Endometrioma, Deep Infiltrating Endometriosis (DIE) and Adenomyosis Lesions Summed by Type on Magnetic Resonance (MR) Images at Cycle 4…
N/A N=35 Endometriosis Group Care
Endometriosis · Pelvic Pain
Primary: PROMIS Pain Interference SF 8a — -1.62 t-score
Phase 4 N=120 The Influence of Adjuvant Medical Treatment of Peritoneal Endometriosis on the Outcome of IVF. A Prospective Randomized Analysis.
Infertility · Endometriosis
Primary: Number of Metaphase II Cells (MII) — 8.2; 8.2 MII cells
N/A N=60 The Association Between Endometriosis, Obesity and nesfatin1
Endometriosis
Primary: Serum Nesfatin 1 — 190; 510 picogram/millilitre — p=0.05
N/A N=56 Enriched Environments in Endometriosis
Endometriosis-related Pain · Endometriosis · Pelvic Pain
Primary: Pain Perception — 7.0; 6.2; 7.2; 5.1 units on a scale
N/A N=120 Endometrial Injury for Unexplained Infertility
Infertility
Primary: Measurement of Uterine Artery Pulsatility Index — 2.40; 2.35 index — p=<0.05
Phase 4 N=1 Ulipristal for Endometriosis-related Pelvic Pain
Endometriosis
Primary: Pelvic Pain — 3.5; 0.2; 3.9 units on a scale — p=<0.05
Phase 4 N=44 Resveratrol for Pain Due to Endometriosis
Endometriosis
Primary: Pain Scores Measured by VAS (Visual Analog Scale) at Day 42. — 3.2; 3.9 units on a scale — p=0.7
Phase 2 N=76 Safety and Efficacy Study of MT-2990 in Women With Endometriosis
Endometrial Related Pain
Primary: Mean Change From Baseline to Week 16 in Nonmenstrual Pelvic Pain Using a Pain Scale Ranges From 0 (None) to 3 (Severe) — -0.28; -0.63 units on a scale
N/A N=118 Endometrial Injury and Single Embryo Transfer
Primary Infertility
Primary: Clinical Pregnancy Rate
Phase 2 N=155 An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis
Endometriosis, Pain
Primary: Change From Baseline in the Monthly Mean Numerical Rating Score (NRS) for Endometriosis Pain at Week 12 — -0.88; -1.19; -1.25 units on a scale — p=0.2311
Phase 4 N=37 Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF
Endometriosis · Infertility
Primary: Patients Who Responded to Controlled Ovarian Hyperstimulation — 7; 5; 3; 5 Participants
N/A N=73 Laparoscopy vs. Robotic Surgery for Endometriosis (LAROSE): a Prospective Randomized Controlled Trial
Endometriosis
Primary: Operative Time — 106.6; 101.6 minutes — p=0.71
Phase 2 N=137 Efficacy and Safety Study of Elagolix in Women With Endometriosis
Endometriosis, Pain
Primary: Change From Baseline in the Monthly Mean Dysmenorrhea Score During the Double-blind Treatment Phase — -0.24; -0.49; -0.37; -1.13 units on a scale — p=0.0262
Phase 3 N=504 Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated Pain
Endometriosis
Primary: Percentage of Participants With a Response for Dysmenorrhea at Month 6 Based on Daily Assessment — 52.1; 78.2; 32.6; 64.4 percentage of participants
Phase 2 N=6 BGS649 Monotherapy in Moderate to Severe Endometriosis Patients
Endometriosis
Primary: Proportion of Patients Who Develop 2 or More Follicles With Diameter 16 mm or Larger — 2; 2; 0 Participants
Phase 2 N=328 A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
Endometriosis
Primary: Percentage of Subjects With 30% or Greater Reduction From Baseline to Week 12 in Mean Overall Pelvic Pain Score (0-3 VRS) — 34.5; 49.4; 61.5; 56.4 percentage of subjects
N/A N=109 An AHEI Dietary Intervention to Reduce Pain in Women With Endometriosis
Endometriosis
Primary: Pain Measurement - Acyclic Pain — 7.1; 7.0; 4.7; 6.7 VAS pain score — p=0.02
N/A N=56 Dyspareunia and Central Sensitization
Endometriosis · Central Sensitisation · Dyspareunia
Primary: Deep Dyspareunia Score — 3.08 scores on a scale
Phase 3 N=872 A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
Endometriosis
Primary: Percentage of Responders at Month 3 Based on Daily Assessment of Dysmenorrhea (DYS) — 19.6; 46.4; 75.8 percentage of participants — p=< 0.001
Phase 3 N=681 A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain
Endometriosis
Primary: Co-Primary Endpoint: Percentage of Participants With a Response for Dysmenorrhea (DYS) at Months 6 and 12 Based on Daily Assessment — 23.7; 62.8; 29.1; 63.8 percentage…
Phase 2 N=142 A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated Pain
Endometriosis
Primary: Change in Dysmenorrhea (DYS) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12 (Percentage Change) — -27.35; -34.72; -41.57; -18.61 percentage of change…
Phase 3 N=815 A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
Endometriosis
Primary: Percentage of Responders at Month 3 Based on Daily Assessment of Dysmenorrhea (DYS) — 22.7; 43.4; 72.4 percentage of participants — p=< 0.001
Phase 3 N=149 Efficacy and Safety, Long-Term Study of NPC-01 to Treat Dysmenorrhea Associated With Endometriosis
Dysmenorrhea
Primary: Patient Response to Treatment for Dysmenorrhea, as Evaluated by Difference of Total Dysmenorrhea Score (Baseline/Pretreatment-End of Treatment) — 2.4 units on a scale
Phase 2 N=354 A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain
Endometriosis
Primary: Change From Baseline Cycle in Mean Overall Pelvic Pain Score at Treatment Cycle 3 — -1.8; -1.6; -1.5; -2.0 score on a scale
Phase 2 N=10 Elagolix for Fertility Enhancement Clinical Trial
Endometriosis · Unexplained Infertility
Primary: Number of Live Births — 3; 1 live births
Phase 2 N=41 Assessing the Endometrial Environment in Recurrent Pregnancy Loss and Unexplained Infertility
Recurrent Pregnancy Loss · Unexplained Infertility
Primary: Abnormal Microbiome Bacterial Sequencing
N/A N=15 Radiofrequency Ablation of Adenomyosis
Adenomyosis
Primary: Post-operative Evidence of Adenomyoma Tissue Ablation Effect by Area (n) as Assessed by Pathological Analysis — 9; 8; 7; 6 treated areas